Feeds:
Posts
Comments

Archive for November, 2008

After Hours

Posted in After Hours, Fun, tagged on November 21, 2008 | Leave a Comment »

Two words: Stephen Colbert. Absolutely hysterical, on new drug treatments.

Read Full Post »

A Tale of Two Shoes

Posted in Business, Fun, Musings, tagged on November 21, 2008 | Leave a Comment »

I have wide feet. Not a big problem (I guess my balance is pretty good) – except when I have to buy shoes. Since I need to find shoes that are WWW, when I find something that fits, I’ll often buy two sets with different colors (say, black and cordovan) because it ain’t easy to [...]

Read Full Post »

Structuring a Sales Training Dept. for Success

Posted in Sales training, Technology, Vendor Selection, eLearning, tagged , on November 21, 2008 | 2 Comments »

In my consulting work with pharmaceutical sales training departments, I have the privilege of working with many quality companies (and quality individuals) – and my goal is to help them succeed.
However, I see a serious “structural deficiency” in many groups that almost guarantees waste, inefficiency, and higher probabilities of failure. Some departments have put the [...]

Read Full Post »

Pharma Marketing this week

Posted in Marketing, Pharma, Pharmaceutical, Social Media, tagged , on November 11, 2008 | Leave a Comment »

J&J gets flamed over the weekend with a social media firestorm over a Motrin ad. Here’s the backstory, with more here. Frankly, I think this constitutes an over-reaction, and may discourage other healthcare companies from putting their toe in the social media water. On the positive side, it certainly demonstrates the enormous potential and viral [...]

Read Full Post »

Pharma News this week (and last)

Posted in Amgen, Amylin, AstraZeneca, Cephalon, Daiichi Sankyo, Eli Lilly, FDA, Healthcare, J&J, Johnson and Johnson, Lilly, Merck, News, Novartis, Pharma, Pharma News, Pharmaceutical, Statins, tagged , , , , , , , , , , , on November 11, 2008 | Leave a Comment »

Roche’s MabThera can help extend CLL patients’ lives. Meanwhile, surprisingly good results for AZ’s lung cancer drug Iressa. But, disappointment for an experimental lung cancer drug being developed by Amgen and Takeda. And, Novartis‘ promising kidney cancer drug Afinitor gets the FDA delay treatment (fuller Novartis pipeline update here).
Glaxo gets U.S. approval for platelet drug [...]

Read Full Post »

After Hours

Posted in After Hours on November 7, 2008 | Leave a Comment »

Wow. Best image of a solar eclipse ever.
This picture cannot be explained. Really.
Lawyers run amuk on a pharma pill disclaimer.
The eyes have it. Scroll left-to-right. Amazing.

Read Full Post »

Recommended…

Posted in Recommendations on November 7, 2008 | Leave a Comment »

The last 2 weeks have been amazingly busy with recommendation requests. Clients have asked me to identify and recommend suppliers for the following needs:

Product eLearning systems
Live Preceptorship programs
International Compliance
Leadership Development
Account Manager training (long-term care)
Cultural Sensitivity Training
Multicultural Selling
Marketing Training
Interactive workshop games

I love my work! Recommending my long-term partners who can take care of these needs, and [...]

Read Full Post »

Pharma Marketing this week

Posted in BMS, Marketing, Novartis, Social Media, tagged , , , on November 6, 2008 | 1 Comment »

Growing number of consumers are rating Rx drugs on-line – Over 60 million adults in the US are using social media applications for healthcare online, and many are speaking directly about products, according to a new Manhattan Research report…more Social media is happening to pharma, folks – but it’s from the outside, not the inside. [...]

Read Full Post »

Pharma News this week

Posted in Amylin, AstraZeneca, BMS, Biotech, Bristol Myers, Cephalon, FDA, GSK, Genzyme, Glaxosmithkline, J&J, Johnson and Johnson, Marketing, Merck, Obesity, Oncology, Pfizer, Pharma, Pharma News, Pharmaceutical, Sanofi-Aventis, Statins, tagged , , , , , , , , , , on November 6, 2008 | Leave a Comment »

Glaxo: more big cuts, and the U.S. HQ needle pointing south – GlaxoSmithKline (GSK) announced that it will reduce its sales personnel by 12% to 7,500 down from 8,500. The company will slash 1,800 jobs resulting in a total of 1,000 layoffs. Some positions have already been eliminated while other personnel will be reassigned to [...]

Read Full Post »